Last reviewed 2026-04-20 · How we verify

OPDIVO QVANTIG (HYALURONIDASE-NVHY)

BRISTOL-MYERS SQUIBB · FDA-approved approved Quality 6/100

OPDIVO QVANTIG (generic name: HYALURONIDASE-NVHY) is a Programmed Death Receptor-1 Blocking Antibody [EPC] drug developed by BRISTOL-MYERS SQUIBB. It is currently FDA-approved.

At a glance

Generic name	HYALURONIDASE-NVHY
Sponsor	BRISTOL-MYERS SQUIBB
Drug class	Programmed Death Receptor-1 Blocking Antibody [EPC]
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

Musculoskeletal pain
Fatigue
Pruritus
Rash
Hypothyroidism
Diarrhea
Cough
Abdominal pain
Hyperglycemia
Decreased appetite
Nausea
Constipation

Serious adverse events

Serious adverse reactions (overall)
Pleural effusion
Pneumonitis
Hyperglycemia
Hyperkalemia
Hemorrhage
Diarrhea
Fatal adverse reactions (myocarditis, myositis, colitis)

Key clinical trials

Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial] (Phase 3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OPDIVO QVANTIG CI brief — competitive landscape report
OPDIVO QVANTIG updates RSS · CI watch RSS
BRISTOL-MYERS SQUIBB portfolio CI

Frequently asked questions about OPDIVO QVANTIG

What is OPDIVO QVANTIG?

OPDIVO QVANTIG (HYALURONIDASE-NVHY) is a Programmed Death Receptor-1 Blocking Antibody [EPC] drug developed by BRISTOL-MYERS SQUIBB.

Who makes OPDIVO QVANTIG?

OPDIVO QVANTIG is developed and marketed by BRISTOL-MYERS SQUIBB (see full BRISTOL-MYERS SQUIBB pipeline at /company/bristol-myers-squibb).

What is the generic name of OPDIVO QVANTIG?

HYALURONIDASE-NVHY is the generic (nonproprietary) name of OPDIVO QVANTIG.

What drug class is OPDIVO QVANTIG in?

OPDIVO QVANTIG belongs to the Programmed Death Receptor-1 Blocking Antibody [EPC] class. See all Programmed Death Receptor-1 Blocking Antibody [EPC] drugs at /class/programmed-death-receptor-1-blocking-antibody-epc.

What development phase is OPDIVO QVANTIG in?

OPDIVO QVANTIG is FDA-approved (marketed).

What are the side effects of OPDIVO QVANTIG?

Common side effects of OPDIVO QVANTIG include Musculoskeletal pain, Fatigue, Pruritus, Rash, Hypothyroidism, Diarrhea. Serious adverse events: Serious adverse reactions (overall), Pleural effusion, Pneumonitis, Hyperglycemia.

Drug class: All Programmed Death Receptor-1 Blocking Antibody [EPC] drugs
Manufacturer: BRISTOL-MYERS SQUIBB — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing